Simulations Plus, Inc. · NASDAQ:SLP
Simulations Plus — LD Micro Main Event Investor Conference 2018
17 slides from Simulations Plus's conference presentation, Dec 4, 2018
Slide 1: LD Micro Main Event Investor Conference
LD MICRO MAIN EVENT INVESTOR CONFERENCE December 4, 2018 Shawn O’Connor Chief Executive Officer John Kneisel Chief Financial Officer Simulations Plus, Inc. shawn@simulations - plus.com Nasdaq: SLP
Slide 2: Safe Harbor Statement
Safe Harbor Statement With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cau
Slide 3: Products & Services
Products & Services Software Product Portfolio • Physiologically - based modeling & simulation platform for drug R&D • Predictive software for >140 properties of chemical formulations • Analytical software for certain biological or disease states • Cloud - based web app for drug development lifecycl
Slide 4: Serving All Stages of the Development Process
Serving All Stages of the Development Process Nasdaq: SLP 4 Our products and services span the entire drug development process from discovery to approval Software Product Portfolio • Physiologically - based pharmacokinetic (PBPK) modeling platform simulates a number of responses in humans and animal
Slide 5: Industry and Regulatory Drivers
• Industry Drivers – Pharmaceutical companies under increasing pressure to reduce the cost and time of drug discovery and development – Pharmaceutical companies targeting drug candidates for smaller markets requiring more efficient development process – Pharmaceutical companies integrating the use o
Slide 6: Growth Strategy
Growth Strategy Nasdaq: SLP 6 ‒ Continue to deliver timely upgrades of existing software products to drive high renewal rates and create new module revenue opportunities ‒ Invest in new software product development to broaden our portfolio of tools our clients require ‒ Attract and hire scientific t
Slide 7: Steady and Consistent Revenue Growth
Steady and Consistent Revenue Growth 7 Nasdaq: SLP More than a decade of consistent revenue growth $11.0 $12.5 $13.8 $14.9 $16.8 $0.4 $5.8 $6.1 $9.2 $12.9 $11.4 $18.3 $19.9 $24.1 $29.7 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 Annual Revenue Software Consulting Key Highlights • Record $29.7M of revenu
Slide 8: Simulations Plus Division (Lancaster)
Simulations Plus Division (Lancaster) 8 Nasdaq: SLP The genesis of the company… providing software, training and consulting services $11.0 $12.3 $13.7 $14.5 $15.7 $0.4 $0.7 $0.8 $1.1 $1.8 $11.4 $13.0 $14.5 $15.6 $17.5 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 Annual Revenue Software Consulting $ in mi
Slide 9: Cognigen Division (Buffalo)
Cognigen Division (Buffalo) 9 Nasdaq: SLP A leading provider of population modeling and simulation services for the pharma and biotech industries $0.2 $0.2 $0.2 $0.2 $5.1 $5.4 $7.1 $7.7 $5.3 $5.6 $7.3 $7.9 FY 2015 FY 2016 FY 2017 FY 2018 Annual Revenue Software Consulting Key Highlights • Market Dri
Slide 10: DILIsym Division (RTP)
$0.2 $0.9 $1.0 $3.4 $1.2 $4.3 FY 2017 FY 2018 Annual Revenue Software Consulting DILIsym Division (RTP) 10 Nasdaq: SLP A leading provider of software products and services in QST and QSP Key Highlights • Acquired in June 2017 • Market Drivers – Accelerated adoption of QST and QSP mechanistic modelin
Slide 11: Financial Overview
Financial Overview Nasdaq: SLP
Slide 12: Consolidated Revenues by Fiscal Quarter
Consolidated Revenues by Fiscal Quarter Nasdaq: SLP 12 $4.0 $4.6 $5.9 $3.7 $4.8 $5.2 $6.0 $4.0 $5.4 $5.7 $6.8 $6.3 $7.1 $7.4 $8.6 $6.7 Q1 Q2 Q3 Q4 2015 2016 2017 2018 $ in millions Organic Annual Revenue Growth 9 - 15% Reported Annual Revenue Growth 9 - 23% including acquisitions
Slide 13: Revenue by Region – FY2018
Revenue by Region – FY2018 Nasdaq: SLP Europe 18% North America 63% Asia 18% South America <1% Japan = 68% India = 16% China = 11% Korea = 1% 13 A global and diversified base of revenue
Slide 14: Profitability by Fiscal Quarter
$0.5 $1.0 $1.9 $0.5 $1.1 $1.2 $1.9 $0.8 $1.4 $1.2 $2.1 $1.2 $1.7 $3.5 $2.4 $1.3 Q1 Q2 Q3 Q4 Net Income 2015 2016 2017 2018 Profitability by Fiscal Quarter Nasdaq: SLP 14 Note: 2Q18 $1.5M tax benefit of deferred tax adjustment $1.2 $2.0 $3.3 $1.2 $2.2 $2.2 $3.3 $1.5 $2.5 $2.3 $3.6 $2.0 $3.2 $3.1 $4.1
Slide 15: Cash Position Remains Excellent
15 Cash Position Remains Excellent (in millions) Over $25 million cash utilized over last four FYs $0.8 $0.8 $0.8 $0.9 $0.9 $0.9 $0.9 $0.9 $0.9 $0.9 $0.9 $0.9 $1.0 $1.0 $1.0 $1.1 $1.1 $2.1 $0.8 $0.7 $0.8 $1.0 $5.0 $1.5 $5.8 $6.1 $6.4 $8.6 $7.2 $7.1 $8.8 $8.0 $8.8 $7.4 $8.2 $6.2 $7.0 $7.5 $7.2 $9.4 $
Slide 16: Products & Services
Products & Services Software Product Portfolio • Physiologically - based modeling & simulation platform for drug R&D • Predictive software for >140 properties of chemical formulations • Analytical software for certain biological or disease states • Cloud - based web app for drug development lifecycl
Slide 17: Thank you for your attention…
Nasdaq: SLP 17 Thank you for your attention… Website: https:// www.simulations - plus.com LinkedIn Company Profile: https://www.linkedin.com/company/95827/
Simulations Plus — LD Micro Main Event Investor Conference 2018 on 6ix